Wohlreich, Madelaine M.

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder

Arnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. J. (2004) · Arthritis & Rheumatism

Fibromyalgia and Chronic Fatigue Syndrome ResearchPain Mechanisms and Treatments

Cited by 624

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial ☆

Russell, J. I., Mease, P. J., Smith, T. R., Kajdasz, D. K., Wohlreich, M. M., Detke, M. J., Walker, D. J., Chappell, A. S., & Arnold, L. M. (2008) · Pain

Fibromyalgia and Chronic Fatigue Syndrome ResearchPain Mechanisms and Treatments

Cited by 367

Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: Secondary analyses of four pooled randomized controlled trials of duloxetine

Marangell, L. B., Clauw, D. J., Choy, E., Wang, F., Shoemaker, S., Bradley, L., Mease, P., & Wohlreich, M. M. (2011) · Pain

Fibromyalgia and Chronic Fatigue Syndrome ResearchPain Mechanisms and Treatments

Cited by 70

Long-Term Safety, Tolerability, and Efficacy of Duloxetine in the Treatment of Fibromyalgia

Mease, P. J., Russell, I. J., Kajdasz, D. K., Wiltse, C. G., Detke, M. J., Wohlreich, M. M., Walker, D. J., & Chappell, A. S. (2010) · Seminars in Arthritis and Rheumatism

Fibromyalgia and Chronic Fatigue Syndrome ResearchPain Mechanisms and Treatments

Cited by 54

Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials

Choy, E. H. S., Mease, P. J., Kajdasz, D. K., Wohlreich, M. M., Crits-Christoph, P., Walker, D. J., & Chappell, A. S. (2009) · Clinical Rheumatology

Fibromyalgia and Chronic Fatigue Syndrome ResearchPharmacovigilance and Adverse Drug Reactions

Cited by 47

Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression

Shelton, R. C., Andorn, A. C., Mallinckrodt, C. H., Wohlreich, M. M., Raskin, J., Watkin, J. G., & Detke, M. J. (2007) · International Clinical Psychopharmacology

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 39

The Efficacy and Tolerability of Duloxetine in the Treatment of Anxious Versus Non-Anxious Depression: A Post-Hoc Analysis of an Open-Label Outpatient Study

Fava, M., Martinez, J. M., Greist, J., Marangell, L. B., Brown, E., Chen, L., & Wohlreich, M. M. (2007) · Annals of Clinical Psychiatry

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 25

The Effect of Duloxetine Treatment on Cognition in Patients With Fibromyalgia

Mohs, R., Mease, P., Arnold, L. M., Wang, F., Ahl, J., Gaynor, P. J., & Wohlreich, M. M. (2012) · Psychosomatic Medicine

Fibromyalgia and Chronic Fatigue Syndrome ResearchCancer-related cognitive impairment studies

Cited by 23

Answers to the Most Common Questions About the Hepatic Safety Profile of Duloxetine

Wohlreich, M. M., Acharya, N., Strombom, I., Kuritzky, L., Robinson, M., Heinloth, A. N., Regev, A., & Wernicke, J. F. (2008) · Postgraduate Medicine

Drug-Induced Hepatotoxicity and ProtectionPharmacovigilance and Adverse Drug Reactions

Cited by 12